Every 10-Q that MARIMED INC (MRMD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MRMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MRMD filings page.
MariMed Inc., a U.S. multi-state cannabis operator, reported for the six months ended June 30, 2026 revenue of $81.4 million, up from $77.4 million a year earlier, with three-month revenue of $41.9 million. Retail and wholesale product sales remained the core of the business.
The company generated Adjusted EBITDA of $7.5 million for the first half of 2026 versus $7.3 million in 2025, but recorded a net loss of $7.3 million attributable to common stockholders and higher interest expense and taxes. Total assets were $197.2 million, against $147.1 million of liabilities and $78.8 million of mortgages and notes payable.
MariMed restructured its Series B preferred obligation into $8.0 million of new notes and new Series B preferred shares, recognizing a $0.7 million gain on extinguishment. A Schedule III reclassification of qualifying cannabis activity reduced income tax expense by about $0.8 million, though IRS tax liens of roughly $7 million remain outstanding and disputed.
MariMed Inc. reported modest revenue growth but remained unprofitable for the quarter ended March 31, 2026. Revenue rose to $39.5 million from $37.9 million a year earlier, driven by both retail and wholesale cannabis product sales. Despite higher sales, the company posted a net loss of $3.8 million, an improvement from a $5.5 million loss in the prior-year quarter, as operating income turned slightly positive but interest and tax expense remained heavy.
Adjusted EBITDA increased to $3.6 million from $2.5 million, reflecting stronger underlying operations. Cash, cash equivalents and restricted cash totaled $7.9 million at quarter end, against $79.3 million of mortgages and notes payable. MariMed restructured its legacy Series B preferred obligation, cancelling the old shares and issuing $8.0 million in new notes plus 26.9 million new Series B preferred shares, recording a $0.7 million gain on extinguishment.
The company continues to operate as a multi-state cannabis producer and retailer and remains subject to cannabis-related tax rules. It fully accrued IRS tax assessments, including liens of approximately $6 million and $1 million, while disputing them through administrative processes.
MariMed Inc. (MRMD) reported Q3 2025 results. Revenue was $40,764,000 with gross profit of $16,363,000. The quarter showed a net loss of $2,941,000 as interest expense and a $2,759,000 tax provision offset operating income of $1,599,000. Adjusted EBITDA was $5,139,000.
Year to date, revenue totaled $118,176,000 with a net loss of $9,815,000. Cash and equivalents were $6,596,000, and net cash provided by operating activities was $4,266,000. Mortgages and notes payable totaled $73,186,000, including $56,324,000 under the CREM loan. Shares outstanding were 394,452,517 as of September 30, 2025; 395,073,625 were outstanding as of November 3, 2025.
The First State Compassion Center acquisition closed March 1, 2025 and contributed $3,900,000 of revenue and $2,400,000 of net income in Q3. In the quarter, 1,155,274 Series C preferred shares converted into 5,776,370 common shares. The company later announced an exit from Missouri operations effective October 28, 2025.